NASDAQ$MLAB
Mesa Laboratories Inc · Q2 2026 earnings
Q2 2026 earnings · · After market close · Investor relations
Briefing
Mesa Labs reported solid second quarter results with revenue growth and improved operating income.
Mesa Laboratories, Inc. announced strong second fiscal quarter results, with total revenues increasing by 5.0% to $60.7 million and operating income surging by 34.7% to $4.7 million. Non-GAAP adjusted operating income excluding unusual items also saw a healthy increase of 6.1% and represented 25.1% of revenues, indicating robust profitability despite macroeconomic uncertainties and specific segment challenges.
- Total revenues increased by 5.0% to $60,737,000 compared to the same period last year.
- Operating income significantly increased by 34.7% to $4,724,000.
- Non-GAAP adjusted operating income excluding unusual items grew by 6.1% and was 25.1% as a percentage of revenues.
- The company achieved 3.7% core organic revenue growth, driven by strong performance in Biopharmaceutical Development, Calibration Solutions, and Clinical Genomics outside of China, offsetting softness in Sterilization and Disinfection Control and headwinds in Clinical Genomics China.
Headline financials
Revenue & EPS history
Mesa Labs · Revenue · Quarterly
$60.7M
Revenue by segment
Mesa Labs · $63.7M total across 4 segments · Q4 2026
- Sterilization and Disinfection Control$29.1M—45.7%
- Calibration Solutions$13.6M—21.3%
- Clinical Genomics$12.2M—19.1%
- Biopharmaceutical Development$8.85M—13.9%
Forward guidance
Mesa Labs anticipates sequential revenue increases in the third fiscal quarter of 2026 and expects continued decreases in Clinical Genomics China revenues for the remainder of the fiscal year. The company plans to reinvest cost savings into the SDC division to fuel long-term growth.
Tailwinds
- Expects revenues to sequentially increase in 3Q26.
- Plans to reinvest approximately $0.9 million of cost savings into SDC to fuel long-term growth.
- Cost reductions are expected to generate $2.3 million of net annualized cost savings.
- Anticipates significant decrease in outside professional services expenses for SDC during the second half of FY26.
- Cost reductions in Clinical Genomics will further expand the Division’s contribution margins in the future while not impacting growth outside of China.
Headwinds
- Expects continued decreases in China revenues for the rest of the fiscal year compared to the same period in the prior year.
- Macroeconomic uncertainty persists.
- Ongoing regulatory headwinds in the CG China diagnostics market.
- Impact of tariffs and foreign currency translation on gross profit percentages.
- Softness in SDC deliveries noted in the current quarter.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q2 2026
+0.1%
Avg return
Earnings day
-0.5%
Avg return
5 days after
-0.1%
Avg return
30 days after
55%
35 / 64 earnings
Positive
+26.6%
Q2 2023
Best reaction
-24.9%
Q1 2026
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | — | — | — | |
| Q3 2026 | +8.7% | +15.9% | +8.8% | |
| Q2 2026 | +2.1% | +6.7% | +3.7% | |
| Q1 2026 | -24.9% | -16.0% | -15.9% | |
| Q4 2025 | -9.3% | -13.5% | -12.8% | |
| Q3 2025 | +2.5% | +10.3% | +3.2% | |
| Q2 2025 | -11.4% | -16.2% | -7.6% | |
| Q1 2025 | +5.8% | +11.8% | +13.4% | |
| Q4 2024 | +13.3% | +5.5% | -3.4% | |
| Q3 2024 | +2.0% | -0.2% | +18.9% | |
| Q2 2024 | +0.1% | -8.8% | +2.0% | |
| Q1 2024 | +8.0% | +10.3% | +11.4% | |
| Q4 2023 | -2.2% | -7.7% | -11.7% | |
| Q3 2023 | -7.4% | -8.6% | -13.5% | |
| Q2 2023 | +26.6% | +31.2% | +39.1% | |
| Q1 2023 | -5.5% | -10.7% | -23.5% | |
| Q4 2022 | -3.7% | -2.7% | -6.1% | |
| Q3 2022 | -3.9% | -2.0% | -5.8% | |
| Q2 2022 | +4.0% | +1.4% | -0.1% | |
| Q1 2022 | +0.4% | -1.4% | -3.8% | |
| Q4 2021 | +4.7% | +6.4% | +9.6% | |
| Q3 2021 | +0.9% | -0.4% | -5.2% | |
| Q2 2021 | -0.4% | +2.7% | +2.1% | |
| Q1 2021 | +2.0% | -1.5% | -1.4% | |
| Q4 2020 | -5.7% | -6.5% | -18.6% | |
| Q3 2020 | -7.2% | -2.4% | -13.9% | |
| Q2 2020 | -0.2% | -4.7% | +3.3% | |
| Q1 2020 | +6.6% | +7.0% | -7.3% | |
| Q4 2019 | -21.1% | -19.3% | -2.3% | |
| Q3 2019 | +0.6% | +3.4% | +2.2% | |
| Q2 2019 | +0.9% | +3.0% | +20.4% | |
| Q1 2019 | -2.7% | -0.3% | +3.5% | |
| Q4 2018 | +16.3% | +15.4% | +31.3% | |
| Q3 2018 | -5.1% | -14.2% | -8.0% | |
| Q2 2018 | -17.2% | -19.7% | -19.7% | |
| Q1 2018 | +5.2% | +1.6% | -2.5% | |
| Q4 2017 | -6.5% | -13.3% | -12.3% | |
| Q3 2017 | +6.4% | +1.4% | +5.2% | |
| Q2 2017 | -1.3% | -0.8% | -1.1% | |
| Q1 2017 | -4.3% | -10.4% | -10.5% | |
| Q4 2016 | +12.7% | +26.5% | +23.1% | |
| Q3 2016 | -4.8% | — | — | |
| Q2 2016 | +1.9% | — | — | |
| Q1 2016 | +13.3% | — | — | |
| Q4 2015 | +2.1% | — | — | |
| Q3 2015 | +0.8% | — | — | |
| Q2 2015 | +10.4% | — | — | |
| Q1 2015 | -2.0% | — | — | |
| Q4 2014 | -4.0% | — | — | |
| Q3 2013 | -0.2% | — | — | |
| Q3 2014 | -0.2% | — | — | |
| Q2 2014 | -0.1% | — | — | |
| Q1 2014 | -3.5% | — | — | |
| Q4 2013 | -0.2% | — | — | |
| Q2 2013 | -1.8% | — | — | |
| Q1 2013 | -0.8% | — | — | |
| Q4 2012 | +2.5% | — | — | |
| Q3 2011 | +1.3% | — | — | |
| Q3 2012 | +1.3% | — | — | |
| Q2 2011 | +1.5% | — | — | |
| Q2 2012 | +1.5% | — | — | |
| Q4 2011 | +0.0% | — | — | |
| Q1 2011 | +0.0% | — | — | |
| Q1 2012 | +0.0% | — | — | |
| Q4 2010 | +0.1% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro